Norroy Showcased Three Oral Presentations at SNMMI 2025, Unveiling Next-Generation Radiopharmaceuticals for Renal Cancer and Beyond

New Orleans, June 2025 — Norroy Bioscience made a strong impact at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in New Orleans with three high-profile oral presentations. Among the highlights was the international debut of Norroy’s fourth-generation small-molecule radiopharmaceutical for renal cancer—the first in its class to demonstrate high sensitivity, specificity and outstanding image quality for diagnosis, and clinical efficacy in therapy, setting a new benchmark in integrated diagnostic and therapeutic (theranostic) development.

The SNMMI Annual Meeting is one of the world’s largest and most influential conferences in the fields of nuclear medicine and molecular imaging. With over 14,000 members of SNMMI, the event serves as a global innovation hub, showcasing cutting-edge research and breakthrough technologies that shape the future of precision medicine.

NY104 Theranostic Program: A Breakthrough Precision Medicine for Renal Cancer

Norroy unveiled some groundbreaking data from its theranostic program ⁶⁸Ga/¹⁷⁷Lu-NY104, a fourth-generation small-molecule radiopharmaceutical pair, targeting carbonic anhydrase IX (CAIX), through two oral presentations at the SNMMI 2025.

Developed through the use of a DOTA chelator to enable the labeling with the radionuclides of ⁶⁸Ga and ¹⁷⁷Lu, NY104 represents a significant advancement in the company’s renal cancer pipeline. Preclinical and early clinical studies have demonstrated the compound’s efficacy and safety. Initial results showed the compound’s superior CAIX-targeting affinity and specificity, with ¹⁷⁷Lu-NY104 achieving robust uptake and sustained retention in tumor tissues.

Furthermore, ⁶⁸Ga-NY104 exhibited remarkable performance, as compared to ¹⁸F-FDG, with advantages in biodistribution, dosimetry, and PET imaging clarity.

"⁶⁸Ga/177Lu-NY104 has established a powerful diagnostic-to-therapeutic continuum for CAIX-expressing renal tumors," said David Mozley, M.D., Chief Medical Officer of Norroy North America. “It not only showcases our innovation strength in radiopharmaceutical development, but also reinforces our global leadership in small-molecule solutions for renal cancer. We are committed to accelerating its global registration and commercial translation.”

First Public Data on NY118: A Small-Molecule Diagnostic for the Billion-Dollar FAP Target

Also debuting at SNMMI 2025 was ⁶⁸Ga-NY118, a novel small-molecule radiodiagnostic agent targeting fibroblast activation protein (FAP)—a highly promising “billion-dollar theranostic target” in oncology. The study was presented in an oral session by Waisi Eng, Ph.D., Chief Technology Officer at Norroy Bioscience.

The compound was radiosynthesized in >95% radiochemical purity and demonstrated excellent in-vitro stability in both PBS and human serum. In preclinical PET/CT imaging studies, ⁶⁸Ga-NY118 exhibited significant tumor accumulation in the FAP-high B-hFAP MC38 mouse models, with the radioactivity uptake markedly higher than that in the low-FAP HepG2 models.

These data underscore the compound’s potential as a powerful diagnostic agent for FAP-expressing tumors, offering high tumor specificity and robust in-vivo stability.

Pioneering the Future of Theranostics

Through the continuous publication in top-tier journals and active participation in major scientific forums, Norroy Bioscience is reinforcing its position at the forefront of nuclear medicine innovation. With a particular focus on small-molecule theranostics for renal and other cancers, the company remains committed to accelerating the clinical translation and expanding its global impact.

Looking ahead, Norroy Bioscience will continue to advance its integrated theranostic pipeline, and strive to deliver precise, effective, and scalable radiopharmaceutical solutions for major diseases like cancer—driving a new era of personalized medicine.